Opendata, web and dolomites

NovAnI SIGNED

Indentification and optimisation of novel anti-infective agents using multiple hit-identification strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NovAnI project word cloud

Explore the words cloud of the NovAnI project. It provides you a very rough idea of what is the project "NovAnI" about.

wall    mycobacterium    molecule    potentially    health    edge    dna    diseases    platform    circumventing    urgently    crossing    bacteria    antimalarial    der    methicillin    coupling    clamp    tuberculosis    crystallographers    chemistry    dnan    medicinal    threat    difficult    synthetic    un    vitamin    causative    importers    builds    infections    place    excellent    repair    return    mrsa    antibacterial    employing    agents    resistant    mode    rapid    dxs    million    explored    energy    agent    anti    protein    resistance    pathogens    positive    collaborations    transporters    thereby    unconventional    scaffolds    polymerase    pharmacologists    synergistic    goals    cutting    me    position    erc    given    organic    exhaustion    infective    serious    incidence    few    expertise    fact    drugs    flexibility    hit    strategies    sliding    inhibitors    give    emergence    small    antituberculotic    negative    humans    combination    deaths    absent    staphylococcus    cell    biochemists    action    biochemical    aureus    drug    first    infectives    peculiar    gram    investment    biosynthetic    provides    selectivity    context    identification    interdisciplinary   

Project "NovAnI" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙367 €
 EC max contribution 1˙499˙367 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2023-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 1˙499˙367.00

Map

 Project objective

Given the rapid emergence of anti-infective resistance, drugs with a novel mode of action are urgently needed. Because of an exhaustion of existing strategies, a low return on investment and the fact that anti-infectives are difficult to develop (e.g., crossing the peculiar cell wall of Mycobacterium tuberculosis), promising un(der)explored targets and unconventional hit-identification strategies are needed.

I have selected three anti-infective targets based on their biochemical context for which few or no small-molecule inhibitors are known:

1) The antimalarial and antituberculotic drug target DXS is part of a unique biosynthetic pathway for pathogens that is absent in humans, thereby circumventing selectivity issues. Both diseases are a serious health threat with around 1.9 million deaths per year. 2) Energy-coupling factor transporters are essential vitamin importers for pathogens such as Staphylococcus aureus, the causative agent of methicillin-resistant Staphylococcus aureus (MRSA) infections. 3) The DNA polymerase sliding clamp DnaN has polymerase and DNA repair activities and is an excellent drug target for the development of antibacterial agents against Gram-negative and –positive bacteria given the low incidence of resistance development.

I will address these targets, employing a unique combination of potentially synergistic hit-identification strategies that take into account protein flexibility, provide access to novel scaffolds and give me a cutting edge for the development of novel anti-infectives.

This ERC proposal builds on my experience with the first two targets and provides an excellent platform for the new target DnaN. My expertise in synthetic organic and medicinal chemistry and established hit-identification strategies together with my collaborations with protein crystallographers, biochemists and pharmacologists place me in an excellent position for not only achieving the goals of this interdisciplinary proposal but also going beyond it.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVANI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVANI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More  

OAlipotherapy (2018)

Long-retention liposomic drug-delivery for intra-articular osteoarthritis therapy

Read More  

CellProbe (2019)

CellProbe: Microfluidic probe for simultaneous tagging and extraction of single cells

Read More